DexCom(US:DXCM) Prnewswireยท2025-11-13 00:55Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed risks related to its continuous glucose monitoring systems during the specified class period from January 8, 2024, to September 17, 2025 [1][2]. Group 1: Allegations Against DexCom - Defendants allegedly made false or misleading statements regarding unauthorized design changes to the G6 and G7 glucose monitoring systems, which compromised their reliability and posed health risks to users [2]. - The enhancements claimed for the G7 device were reportedly overstated, and the company downplayed the severity of issues related to the G7 devices [2]. - The alleged misconduct has led to increased regulatory scrutiny and potential legal, reputational, and financial harm for DexCom [2]. Group 2: Legal Process for Investors - Investors in DexCom can seek to be appointed as lead plaintiffs by December 26, 2025, or remain absent class members [3]. - The lead plaintiff will represent the interests of all class members and select legal counsel for the case [3]. - Participation as a lead plaintiff does not affect the ability of investors to share in any recovery from the lawsuit [3].